Published Online: Tuesday, April 1, 2008

The American Association of Colleges of Pharmacy (AACP) will recognize 4 student-led community-engaged service projects that provide care to the underserved with the inaugural AACP Student Awards for Community Engaged Service.

Sponsored by Teva Pharmaceuticals, this annual award program will recognize a community-engaged service program developed and delivered by doctor of pharmacy students enrolled at AACP member colleges or schools of pharmacy. The award program is intended to encourage pharmacy students and faculty to design and build programs of community-engaged service learning, delivering patient education about medication use, expanding access to affordable medication, and improving the public's health.

"At Teva, one of the most important things we do is to make health care accessible," said William S. Marth, president and chief executive officer of Teva North America. "This award program encourages students to help educate consumers and also improve access to affordable drugs."

The 4 inaugural awards will be presented at the 2009 AACP Interim Meeting in Arlington, Virginia. In addition to receiving a commemorative prize, the winning pharmacy college or school will also receive $10,000 to be used exclusively to support the expansion of the recognized program or new community-engaged service projects at the school. Additional prizes include a $5,000 financial stipend administered to participating students to be used for enhancing or sustaining the recognized program or for travel support to attend and present their projects at professional meetings.

For more information about the awards, visit www.aacp.org, and click on the For Students and Applications or the For Faculty Section.

Latest Articles
Pharmacies are rated as some of the best places to receive top-notch customer service in America.
Often caused by acid reflux, eosinophilic esophagitis is an emerging inflammatory disease that is generally unresponsive to proton pump inhibitor therapy.
Carlos Aquino, founder and president of PharmaDiversion LLC, discusses timing of inspections from the Drug Enforcement Administration.
The FDA has again rejected AMAG Pharmaceuticals’ application for a single-dose version of hydroxyprogesterone caproate injection (Makena) to reduce the risk of preterm birth for at-risk women.
Latest Issues